Prevención del Cáncer Cervicouterino. Protocolo para Implementar la Distribución y Redistribución del Kit del Test de VPH en Contexto Programático

Objectives

Argentina’s National Cancer Institute, within the Ministry of Health, is mandated to develop and implement cancer-control policy and coordinate integrated prevention and control actions.[1]Within this remit, the cervical cancer strategy aims to expand equitable, quality-assured access to human papillomavirus (HPV)-based screening in the public health system, strengthen early detection, and support the prevention and eventual elimination of cervical cancer, particularly among women facing unequal access to screening.[2][3][4]

• Implement HPV testing as the primary cervical cancer screening method, following its approval in 2011 and progressive introduction from Jujuy in 2012 to other jurisdictions from 2014.[1]
• Provide territorial distribution and redistribution of basic HPV test kits to provinces and municipalities using HPV screening, with the aims of guaranteeing access, quality and equity.[3]
• Apply evidence-based quality standards, health-worker training and rational resource use to ensure safe, accurate and sustainable screening delivery.[2][5][6]
• Ensure appropriate kit quantities by basing forecasts on the number of women newly screened in the preceding year and each jurisdiction’s coverage target.[7]
• Protect sample collection, conservation and processing by maintaining cold-chain conditions, secure traceability, suitable storage, functioning equipment and laboratory readiness.[8][5]
• Maintain continuity of screening by monitoring stocks, anticipating temporary shortages and reallocating kit components between jurisdictions when necessary.[9][10]
• Centralise HPV, cytology and histology reading in provincial or municipal pathology services in order to simplify logistics, improve reading quality and shorten result-delivery times.[11]

The strategy is supported by implementation evidence from the Jujuy Demonstration Project, which found that HPV testing doubled detection of high-grade lesions and cancer without increasing the existing workforce for sample collection and processing.[11]The project also reported better compliance with the recommended screening starting age, fewer unsatisfactory or discarded samples and improved reading quality than cytology.[11]The supplied material does not set national outcome targets, a timetable for elimination, or quantified coverage objectives beyond jurisdictional coverage-based kit forecasting.[3][7]

Implementation

The delivery model combines nationally coordinated procurement, territorial supply management and laboratory-centred service delivery. The National Programme for Cervical Cancer Prevention and the National Cancer Institute coordinate distribution, redistribution, stock monitoring and technical support with provincial and municipal programme leads, HPV laboratory managers, suppliers and the National HPV Reference Laboratory within the National Administration of Laboratories and Health Institutes Dr Carlos Malbrán.[1][3][4]HPV samples are processed through laboratories equipped under National Cancer Institute supervision, with fourteen such laboratories reported in the source.[1]

• Deliver HPV test kits, including determinations, consumables and collection tubes, to selected provincial or municipal laboratories through supplier arrangements established by the national programme and institute.[12]
• Assign laboratory heads or responsible officers to receive diagnostic kits, verify their quantity and quality, preserve correct storage conditions and manage kit stock; assign collector-tube oversight to the relevant jurisdictional focal point or stock manager where tubes are received separately.[12][13]
• Coordinate suppliers, laboratories and national programme staff on delivery dates, quantities, equipment and pre-dispatch provision of the digital test manual.[7][8]
• Check packaging integrity, refrigerants, cold-chain continuity, supply quantities, batch numbers and equipment serial numbers on receipt, and refrigerate temperature-sensitive supplies immediately.[8]
• Provide storage and processing equipment on loan where agreements with jurisdictions permit it, with receiving laboratories responsible for its appropriate use and conservation.[7]
• Install equipment and train laboratory technical staff through the provider, including theoretical and practical instruction on operation, procedures and safety; retain accessible instructions for sample preparation and processing.[5][6]
• Report delivery discrepancies, equipment or kit contingencies, and threats to sample preservation to the national programme and, where applicable, the supplier’s after-sales service.[5][14]
• Request additional supplier training for new laboratory staff and notify the national programme within 30 days.[6]

Stock governance is a central operational mechanism. Laboratories record samples received, accepted, rejected, processed and awaiting processing, alongside available determinations and expiry dates, and submit monthly stock reports to the national programme and institute.[13]Jurisdictions similarly record collector tubes received, delivered, consumed, rejected and discarded, with available stock and expiry dates.[13][10]The national programme compares reported and estimated stock and follows up discrepancies with laboratory or tube-stock managers.[13][10]

• Trigger clearing, meaning inter-jurisdictional kit redistribution, when any kit component is expected to cover only two months of screening; assess provider availability and administrative and financial feasibility before authorisation.[10][15]
• Select provider jurisdictions able to sustain their own screening, favouring nearby or more cost-effective transport routes, and provide national technical support for logistics.[10]
• Maintain cold-chain and traceability controls during redistribution by documenting quantities, batch numbers, expiry dates, packing and collection times, dispatch documentation and receipt verification.[16][17]
• Suspend conventional and self-sampling HPV screening during a stock-out, register incoming HPV and triage cytology specimens, store HPV samples according to supplier specifications, continue triage-cytology reading and submit weekly information on stored samples and daily freezer-temperature checks.[18]
• Use determinations with the nearest expiry date first after replenishment, and consider clearing where stored samples may expire before a new distribution arrives.[18][19]

Quality assurance includes programme indicators for HPV laboratory diagnostic quality, technical reports after training, and on-site audits where required to identify problems in sample preparation or test processing.[6]The source specifies operational reporting, stock control, traceability and contingency procedures, but does not provide a complete indicator set, performance targets, evaluation schedule, sanctions or detailed formal accountability framework.[7][6][13]

Monitoring & Evaluation

Monitoring focuses on maintaining the quality, continuity and traceability of human papillomavirus (HPV) testing through laboratory-performance indicators, stock control, documented receipt checks, contingency reporting and coordination by the National Programme for the Prevention of Cervical Cancer and the National Cancer Institute (PNPCC-INC).[1][6][13]

• Monitor HPV laboratory diagnostic quality through programme indicators and arrange on-site audits where required to identify problems in sample preparation or test processing.[6]
• Record samples received, accepted, rejected, processed and awaiting processing, alongside available test determinations and expiry dates; submit these stock data monthly to PNPCC-INC.[13]
• Report monthly collector-tube stocks, including quantities received, delivered, consumed, rejected and discarded, expiry dates and jurisdictional stock availability.[13][10]
• Compare reported and estimated stock, with PNPCC-INC contacting laboratory or collector-tube stock managers to reconcile discrepancies.[13][10]
• Issue an alert when any kit component reaches stock sufficient for approximately two months of screening, enabling PNPCC-INC to assess redistribution options and associated feasibility.[15]
• Verify supply receipt against delivery documentation, including quantities, batch numbers and equipment serial numbers; check packaging integrity, refrigerants and cold-chain continuity, and immediately refrigerate supplies requiring cold storage.[8]
• Maintain shipment traceability by recording cooler-loading and collection times, checking boxes against dispatch forms, returning signed digital documentation, and monitoring transport duration against manufacturer cold-chain requirements.[17]
• Report kit, equipment, storage and processing contingencies to PNPCC-INC and, where relevant, the supplier; responses to some incidents are subject to deadlines agreed between parties.[7][14]
• Submit a technical report after laboratory training, covering personnel trained, training hours and content, and strengths and weaknesses in HPV-sample processing.[6]
• Conduct daily freezer-temperature checks during stock-outs and provide weekly reports on stored samples, including numbers received, storage date and temperature, expiry dates and cumulative totals.[18]

Evidence from the three-year Jujuy Demonstration Project indicated that HPV testing doubled detection of high-grade lesions and cancer without increasing the workforce used for sample collection and processing.[11]The project also reported improved adherence to the recommended screening starting age, fewer unsatisfactory or discarded samples and better reading quality than cytology.[11]The source does not specify indicator definitions or targets, a comprehensive evaluation schedule, a surveillance framework, formal outcome measures, or sanctions for non-reporting.[2][4][10]

Costing & Financing

Resource management centres on procuring, distributing, storing and, where necessary, redistributing HPV test kits, consumables, collection tubes and laboratory equipment to sustain equitable screening access.[1][12][10]Kit requirements are estimated from the number of women newly screened in the preceding year and the jurisdictional coverage target, while equipment allocation reflects expected reagent use and sample-processing volumes.[7]

• Purchase and distribute essential supplies for cancer detection, diagnosis and treatment through the National Cancer Institute’s territorial remit.[1]
• Provide storage and processing equipment on loan where agreements between the National Cancer Institute and jurisdictions establish this arrangement, with recipient laboratories responsible for its appropriate use and conservation.[7]
• Supply laboratory-training materials separately from test kits through the provider, without a stated monetary valuation.[6]
• Use clearing arrangements to transfer kit components between jurisdictions when shortages and excess stocks coexist, selecting a supplying jurisdiction able to preserve its own screening activity.[10]
• Favour nearby or otherwise more cost-effective logistical routes when redistributing kits in order to reduce shipment costs.[10]
• Assess administrative and financial feasibility before authorising a clearing procedure, and manage acquisition and logistics for coolers, refrigerants and cardboard boxes when these are unavailable in the supplying jurisdiction.[15][16]
• Plan national acquisition of HPV supplies against projected jurisdictional consumption and procurement lead times.[20]

Underfunding, high prices, supply shortages in health services and contamination during traceability are identified as barriers to timely and correct supply distribution and use.[2]Laboratory relocation during an active procurement process may have legal and financial implications, although no amount is given.[9]The source does not provide budgets, expenditure, unit prices, financing allocations or sources, funding targets or quantified gaps, nor economic assumptions.[2][12][5]